UCB gets access to rights for an antibody programme from WILEX for non-oncology indications
| PDF Download
Munich, Germany / Brussels, Belgium, 10 July 2013 – WILEX AG (ISIN DE0006614720 / WL6 / FSE) and UCB announced today that UCB has acquired an antibody programme from WILEX’ preclinical portfolio originally obtained from UCB in 2009. UCB has the right to develop the antibodies from the programme in any indication outside the field of oncology, while WILEX keeps the rights to develop for oncology indications.
WILEX will be reimbursed an undisclosed amount for its development costs to date and shall be eligible for future, undisclosed development, regulatory and commercial milestone payments as well as royalties.
UCB and WILEX will continue to share data regarding the programme through the existing development committee structures. UCB will be working on these antibodies in immunology/inflammation and, as part of the strategic partnership between the two companies, will make available to WILEX the relevant data to assist WILEX in oncology.
Professor Olaf G. Wilhelm, Chairman of the Executive Management Board of WILEX AG, commented, “An identified lead antibody and generated data attracted UCB to purchase the rights to indications outside oncology at such an early stage which is not only a validation of our capabilities but also proof of our excellent partnership with UCB.”
Ismail Kola, Executive Vice President and Chairman of New Medicine at UCB, said: “The pre-clinical work originated by UCB and continued by WILEX researchers to identify the immunology potential of one of their programs is of great interest to us. Leveraging UCB’s scientific expertise in immunology, we will now take the program forward and explore it further in immunology indications where there are severe unmet needs.”
WILEX AG is a biopharmaceutical company based in Munich, Germany. Focused on oncology, the Company develops diagnostic and therapeutic product candidates for the specific detection and targeted treatment of various types of cancer. In the field of therapeutics, WILEX develops antibodies and small molecules. (RENCAREX®: Phase III, MESUPRON®: Phase II, WX-554: Phase Ib/II and WX-037: preclinical). In the field of diagnostics, REDECTANE® is an antibody-based imaging agent that is currently in a Phase III programme. The Company also has a portfolio of biomarker assays that are marketed via its US subsidiary WILEX Inc. under the brand Oncogene Science. WILEX’s subsidiary Heidelberg Pharma GmbH offers preclinical contract research services and a highly promising antibody drug conjugate (ADC) technology platform. The business model of WILEX comprises research and product development as well as the commercialisation of its activities. WILEX’s customers and partners include leading international pharmaceutical companies. Website: http://www.WILEX.com, ISIN DE0006614720 / WKN 661472 / Symbol WL6.
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 9000 people in approximately 40 countries, the company generated revenue of EUR 3.4 billion in 2012. UCB is listed on Euronext Brussels (symbol: UCB).
|Katja Arnold (CIRO)
Corporate Communications & IR
81675 Munich, Germany
Tel.: +49 (0)89-41 31 38-126
|Antje Witte / Alexandra Deschner
UCB, Investor Relations
T +32 2 559 9414, email@example.com
T +32 2 559 9683, firstname.lastname@example.org
Allée de la Recherche, 60
1070 Brussels, Belgium
RPM Brussels 0403.053.608
This communication contains certain forward-looking statements relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will”, “should”, “future”, “potential” or similar expressions or by a general discussion of the Company’s strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward- looking statements to reflect future events or developments.